Möchten Sie immer auf dem neuesten Stand bleiben?

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...

Therini Bio doses first patients in Ph1b trial evaluating novel anti-inflammatory therapy, THN391, in DME, and advances fibrin/VEGF bispecific THN622

IQity partners with Sightpath Medical to bring advanced ophthalmic technology to surgeons throughout the USA

Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO’s introduction to the broader ophthalmology community at ASCRS...

Eye Summit™ 2026 brings 20+ experts to share how to prevent vision loss, including strategies for macular degeneration, dry eye, glaucoma and brain health

Gosselies, Belgium, May 05, 2026 (GLOBE NEWSWIRE) -- Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the goal of slowing,...

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn., May ...